Dynavax Technologies | DVAX - Loan Capital



Dynavax Technologies reported $220.75M in Loan Capital for its fiscal quarter ending in June of 2025.


Loan Capital Change Date
AbbVie USD 64.53B 4.19B Mar/2025
Adma Biologics USD 73.4M 1.06M Jun/2025
Amgen USD 53.76B 253M Jun/2025
AstraZeneca USD 25.99B 1.9B Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
BioMarin Pharmaceutical USD 596.16M 512K Jun/2025
Bristol-Myers Squibb USD 44.47B 1.69B Jun/2025
Dynavax Technologies USD 220.75M 39.75M Jun/2025
Gilead Sciences USD 22.14B 6M Jun/2025
Glaxosmithkline GBP 15.3B 667M Jun/2025
Merck USD 33.97B 484M Jun/2025
Neurocrine Biosciences USD 0 0 Dec/2024
Novartis USD 24.06B 2.4B Jun/2025
Pfizer USD 57.5B 137M Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Jun/2025
Roche Holding CHF 32.1B 1.94B Dec/2024
Sarepta Therapeutics USD 1.14B 1.17M Jun/2025
TG Therapeutics USD 245.04M 608K Jun/2025
Vertex Pharmaceuticals USD 112.8M 1.2M Dec/2024